LY3300054 + ramucirumab

LY3300054 + ramucirumab is an investigational combination regimen consisting of LY3300054, a fully human monoclonal antibody targeting programmed cell death ligand 1 (PD-L1), and ramucirumab, a fully human monoclonal antibody directed against vascular endothelial growth factor receptor 2 (VEGFR-2). LY3300054 functions as an immune checkpoint inhibitor by binding to PD-L1 and blocking its interaction with PD-1, thus enhancing anti-tumor immune responses. Ramucirumab acts as an antiangiogenic agent by inhibiting VEGF-mediated angiogenesis, thereby suppressing tumor vascularization. This combination was evaluated for safety and antitumor activity in patients with advanced, refractory solid tumors, demonstrating manageable adverse events without unexpected safety signals when administered together[1].

Other names

anti-PD-L1 antibody LY3300054anti-PD-L-1 antibody LY3300054anti-PD-L 1 antibody LY3300054ramucirumab